Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
BACKGROUND
The prognostic value of quantitative 18F-fluoro-2-deoxy-D-glucose (FDG) uptake on positron emission tomography (PET) is controversial in unselected patients with non-small cell lung cancer (NSCLC). We assessed the in vivo FDG uptake, measured as maximum pixel standardized uptake value (SUVmax), in stages I and II NSCLC for its prognostic value and association with in vitro quantitative morphology of tumor vitality.


METHODS
Prospective FDG-PET data were available in 91 consecutive patients operated for pathologic stages I and II NSCLC. Quantitative morphology was performed of tumor architecture, tumor cell density and immunohistochemical biomarkers for apoptosis (caspase-3), cell proliferation (Ki-67), hypoxia (HIF-1alpha), cellular pH regulation (carbonic anhydrase IX [CAIX]), and microvessel density (CD31).


RESULTS
SUVmax >or= median and SUVmax partial volume corrected for lesion size (PVC SUVmax) >or= median were associated with an increased risk of death in univariable analysis. After correcting for stage, tumor size and age in multivariable analysis, only PVC SUVmax >or= median remained significant. The strong significant association between tumor size and SUVmax weakened after PVC, suggesting that an important amount of SUVmax can be simply explained by tumor size, which is less in case for PVC SUVmax that associates more to the tumor cell density. In multivariable logistic regression analysis, a PVC SUVmax >or= median could be explained by high Ki-67 and high-CAIX length density.


CONCLUSIONS
PVC SUVmax has a prognostic value in completely resected stages I and II NSCLC. A high-quantitative FDG uptake is associated with characteristics of tumor vitality such as high tumor cell density, high cell proliferation, and extracellular acidosis.
Dooms
Christophe
C
Department of Pulmonology and Leuven Lung Cancer Group, University Hospitals Leuven, Belgium. christophe.dooms@uz.kuleuven.ac.be
van Baardwijk
Angela
A
Verbeken
Eric
E
van Suylen
Robert Jan
RJ
Stroobants
Sigrid
S
De Ruysscher
Dirk
D
Vansteenkiste
Johan
J
D014408:Biomarkers, Tumor / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D016009:Chi-Square Distribution; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D007150:Immunohistochemistry; D016015:Logistic Models; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D008297:Male; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D015996:Survival Rate; D014055:Tomography, Emission-Computed / Q000379:methods*
D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18